Antimicrobial treatment of asymptomatic carriers of verocytotoxin-producing Escherichia coli: an empiric study

Scand J Infect Dis. 2005;37(1):61-3. doi: 10.1080/00365540510026427.

Abstract

Antimicrobial treatment of acute infection caused by verocytotoxin toxin-producing Escherichia coli (VTEC) is controversial due to risk of inducing haemolytic uraemic syndrome. We review the treatment of 9 persons who experienced serious social problems due to prolonged, asymptomatic carriage of non-O157 VTEC. Eradication of VTEC was successful and without complications.

MeSH terms

  • Adult
  • Ampicillin / adverse effects
  • Ampicillin / therapeutic use*
  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / therapeutic use*
  • Carrier State / drug therapy*
  • Child, Preschool
  • Ciprofloxacin / adverse effects
  • Ciprofloxacin / therapeutic use*
  • Denmark / epidemiology
  • Escherichia coli Infections / drug therapy*
  • Escherichia coli Infections / epidemiology
  • Female
  • Hemolytic-Uremic Syndrome / chemically induced
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Serotyping
  • Shiga Toxins / classification*

Substances

  • Anti-Infective Agents
  • Shiga Toxins
  • Ciprofloxacin
  • Ampicillin